Vasomotor Symptoms of Menopause Market - Forecast(2021 - 2026)

Report Code: HCR 0597 Report Format: PDF + Excel (Delivery in 48 Hrs)

Vasomotor Symptoms of Menopause Market Overview

The Vasomotor Symptoms of Menopause Market size is forecast to reach $893.15 million by 2025, growing at a CAGR of 6.51% during the forecast period 2020-2025. Vasomotor symptoms of menopause are the actions that are related to nerves and muscles that cause the blood vessels to dilate. Vasomotor symptoms of menopause are a transition between two phases: perimenopause and menopause. Hormonal imbalance which leads to premature menopause and increasing awareness of the vasomotor symptoms of menopause is the major factor driving the growth of the market. The rise in the number of companies investing in clinical trial candidates and increasing investments in research and development is set to further enhance the overall market demand for the Vasomotor Symptoms of Menopause Market during the forecast period 2020-2025.

Vasomotor Symptoms of Menopause Market Report Coverage

The report: “Vasomotor Symptoms of Menopause Market Forecast (2020-2025)”, by IndustryARC, covers an in-depth analysis of the following segments of the Vasomotor Symptoms of Menopause Market. 
By Therapy Type: Estrogen, Progesterone, Combination, OTC hormone, Anti-Depressants, and Others 
By Distribution Channel: Pharmacies, Hospitals, Clinics, and Others
By Geography: North America, Europe, Asia Pacific, and Rest of the World (RoW)

Key Takeaways

  • North America dominated the Vasomotor Symptoms of Menopause Market in 2019 owing to the vast awareness towards novel treatment and more women are actively seeking treatment related to menopause. The Vasomotor Symptoms of Menopause Market scope for different regions will be provided in the final report.
  • Increasing incorporation of innovation in the industry and high investment in research and development is likely to aid in the market growth of the Vasomotor Symptoms of Menopause Market.
  • Detailed analysis of the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Vasomotor Symptoms of Menopause Market report.
  • Side effects and disruption in the supply chain of the drug is poised to create hurdles for the Vasomotor Symptoms of Menopause Market.

Vasomotor Symptoms of Menopause Market Segment Analysis - By Therapy Type

The Hormonal segment held the largest share in the Vasomotor Symptoms of Menopause Market in 2019 and is estimated to grow at a CAGR of 7.13% during the forecast period 2020-2025 owing to the growing inclination of companies towards this therapy for the treatment and management of vasomotor symptoms. Estrogen is a hormone that plays various roles in the body. In females, it helps develop and maintain both the reproductive system and female characteristics, such as breasts and pubic hair. It contributes to cognitive health, bone health, the function of the cardiovascular system, and other essential bodily processes. However, most people know it for its role alongside progesterone in female sexual and reproductive health. Hormonal is set to be the highest growing segment and is estimated to register the highest CAGR during the forecast period 2020-2025.

Vasomotor Symptoms of Menopause Market Segment Analysis - By Geography

North America dominated the Vasomotor Symptoms of Menopause Market in 2019 with a share of more than 43.17% followed by the Asia Pacific owing to the vast awareness towards novel treatments and more number of women actively seeking treatment-related menopause.

However, Asia Pacific is estimated to grow at a higher CAGR during the forecast period 2020-2025 owing to the initiatives taken by government bodies towards the overall health of women and the increasing medical tourism. Favourable healthcare policies are also increasing the growth of the Vasomotor Symptoms of Menopause Market in this region.

Vasomotor Symptoms of Menopause Market Drivers  

Hormonal imbalance which leads to the premature menopause

Hormonal imbalance which leads to premature menopause is increasing the growth of the Vasomotor Symptoms of Menopause Market. As reproductive functions play out over time hormone levels take a plunge, triggering the onset of menopause and common hormone imbalances associated with the change of life. If stress takes center stage in our lives and becomes chronic, cortisol floods the system, and total hormone production lags. This forces the body to steal from its supplies of available progesterone, to make more cortisol, thus depleting this key balancing hormone with obvious implications for estrogen dominance. Prolonged stress tears up our bones, melts our muscles, robs us of strength and energy, lowers our libido, and overwhelms our immunities, putting us at serious risk for chronic illness and autoimmune disease. Thus, increasing the growth of the Vasomotor Symptoms of Menopause Market during the forecast period 2020-2025.

More number of women are actively seeking treatment related to menopause

More number of women are actively seeking treatment related to menopause is increasing the growth of the Vasomotor Symptoms of Menopause Market. To relieve vaginal dryness, estrogen can be administered directly to the vagina using a vaginal cream, tablet, or ring. This treatment releases just a small amount of estrogen, which is absorbed by the vaginal tissues. Certain antidepressants related to the class of drugs called selective serotonin reuptake inhibitors (SSRIs) can decrease menopausal hot flashes. Certain antidepressants related to the class of drugs called selective serotonin reuptake inhibitors (SSRIs) can decrease menopausal hot flashes. A low-dose antidepressant for the management of hot flashes can be useful for women who can't take estrogen for health reasons or for women who need an antidepressant for a mood disorder. Thus, increasing the growth of the Vasomotor Symptoms of Menopause Market during the forecast period 2020-2025.

Vasomotor Symptoms of Menopause Market Challenges

Side effects and disruption in the supply chain of drug 

Some of the factors that is set to impede the growth of the Vasomotor Symptoms of Menopause Market are side effects and disruption in the supply chain of the drug.
 

Vasomotor Symptoms of Menopause Market Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and R&D activities are key strategies adopted by players in the Vasomotor Symptoms of Menopause Market. In 2019, the Vasomotor Symptoms of Menopause Market share is consolidated by the top ten players present in the market. Vasomotor Symptoms of Menopause Market, the top 10 companies are Eli Lilly and Company, Procter & Gamble, Pfizer Inc., Ausio pharmaceuticals, LLC, EndoCeutics, Inc., Mithra Pharmaceuticals, Pfizer Inc., Novartis AG, Novo Nordisk A/S, Merck KGaA, Emcure Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd, and Edgemont Pharmaceuticals LLC among others.

Acquisitions/Product Launches

  • In April 2020, Mithra Pharmaceuticals, a Belgium-based company announced an update on the Donesta Phase III clinical program called “E4 Comfort”, which aims at enrolling approximately 2200 menopausal women (40-65 years). 

1. Vasomotor Symptoms of Menopause Market - Overview
    1.1 Definitions and Scope
2. Vasomotor Symptoms of Menopause Market - Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by Therapy Type
    2.3 Key trends by Geography
3. Vasomotor Symptoms of Menopause Market – Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Vasomotor Symptoms of Menopause Market - Startup Companies Scenario Premium
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Vasomotor Symptoms of Menopause Market – Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Vasomotor Symptoms of Menopause Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes 
7. Vasomotor Symptoms of Menopause Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Vasomotor Symptoms of Menopause Market – By Therapy Type(Market Size –$Million/$Billion)
    8.1 Hormonal
        8.1.1 Estrogen
        8.1.2 Progesterone
        8.1.3 Combination
        8.1.4 OTC Hormone
        8.1.5 Others
    8.2 Non Hormonal
        8.2.1 Antidepressants
            8.2.1.1 Fluoxotenine
            8.2.1.2 Venlafaxine
            8.2.1.3 Others
        8.2.2 Others
9. Vasomotor Symptoms of Menopause Market – By Distribution Channel (Market Size –$Million/$Billion)
    9.1 Pharmacies
    9.2 Hospitals
    9.3 Clinics
    9.4 Others
10. Vasomotor Symptoms of Menopause Market - By Geography (Market Size –$Million/$Billion) 
    10.1 North America
        10.1.1 U.S.
        10.1.2 Mexico
        10.1.3 Canada
    10.2 Europe
        10.2.1 U.K.
        10.2.2 France
        10.2.3 Germany
        10.2.4 Italy
        10.2.5 Spain
        10.2.6 Rest of Europe
    10.3 Asia Pacific
        10.3.1 China
        10.3.2 India
        10.3.3 Japan
        10.3.4 South Korea
        10.3.5 Australia & New Zealand
        10.3.6 Rest of APAC
    10.4 Rest of the World
        10.4.1 Middle East
        10.4.2 Africa
        10.4.3 South America
11. Vasomotor Symptoms of Menopause Market - Entropy
12. Vasomotor Symptoms of Menopause Market – Industry/Segment Competition Landscape   Premium 
    12.1 Market Share Analysis
        12.1.1 Global Market Share – Key Companies
        12.1.2 Market Share by Region – Key companies
        12.1.3 Market Share by Countries – Key Companies
        12.1.4 Best Practices for Companies
13. Vasomotor Symptoms of Menopause Market – Key Company List by Country Premium Premium
14. Vasomotor Symptoms of Menopause Market Company Analysis
    14.1 Company 1
    14.2 Company 2
    14.3 Company 3
    14.4 Company 4
    14.5 Company 5
    14.6 Company 6
    14.7 Company 7
    14.8 Company 8
    14.9 Company 9
    14.10 Company 10
"*Financials for private companies would be provided on a best efforts basis”.